Subject(s)
Cosmetic Techniques/adverse effects , Crowns/adverse effects , Dermal Fillers/adverse effects , Iatrogenic Disease , Subcutaneous Emphysema/diagnosis , Adult , Dermal Fillers/administration & dosage , Durapatite/administration & dosage , Durapatite/adverse effects , Face , Female , Humans , Molar , Neck , Subcutaneous Emphysema/etiology , Subcutaneous Tissue/diagnostic imaging , Time Factors , Time-to-Treatment , Tomography, X-Ray ComputedABSTRACT
Herpes zoster is uncommon in the pediatric population. We report a case of herpes zoster in a 2-year-old boy who received the live attenuated varicella zoster virus vaccination at his 12-month pediatric visit. The child was treated with acyclovir and recovered without complications.
Subject(s)
Chickenpox Vaccine , Herpes Zoster/immunology , Herpesvirus 3, Human/immunology , Vaccination , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Chickenpox Vaccine/adverse effects , Child, Preschool , Herpes Zoster/drug therapy , Herpes Zoster/virology , Herpesvirus 3, Human/isolation & purification , Herpesvirus 3, Human/physiology , Humans , Male , Vaccines, Attenuated/adverse effects , Virus Activation , Virus LatencyABSTRACT
Trimethylaminuria is a rare, autosomal recessive, metabolic disorder that results in accumulation of trimethylamine (TMA), which smells like rotten fish. The chemical is excreted in sweat and urine owing to a deficiency in the enzyme flavin monooxygenase 3 (FMO3). We report a case of trimethylaminuria in a 12-year-old girl. The patient failed treatment with diet and hygiene modification, but achieved symptomatic improvement after a four-month course of metronidazole.
Subject(s)
Metabolism, Inborn Errors/diagnosis , Methylamines/urine , Anxiety Disorders/complications , Child , Female , Humans , Hygiene , Hyperhidrosis/complications , Metabolism, Inborn Errors/diet therapy , Metabolism, Inborn Errors/drug therapy , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/urine , Metronidazole/therapeutic use , Oxygenases/deficiency , Oxygenases/geneticsSubject(s)
Hepatitis C, Chronic/complications , Immunoglobulin G/therapeutic use , Psoriasis/complications , Psoriasis/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Etanercept , Humans , Immunoglobulin G/adverse effects , Male , Middle AgedABSTRACT
AIM: The aim of this study was to assess whether patients with colorectal cancer (CRC) are aware of the risk to family members and to test an educational intervention. METHODS: CRC patients were surveyed regarding their cancer, family history, understanding of familial risk of CRC, and knowledge of existing screening guidelines for their relatives. An educational intervention was mailed to them and 6 months later they were resurveyed. RESULTS: Of 253 CRC patients who agreed to participate, only 120 (47.4%) knew that their first-degree relatives were at increased risk for CRC. African-American (AA) race, educational background, income, and previous family history of CRC were significant predictive factors on univariate analysis, but only AA race remained significant on multivariate analysis. Two hundred two patients received the educational intervention and were resurveyed. The understanding of family risk did not improve with this intervention. CONCLUSION: Most CRC patients do not know about their family members' risk. Better educational tools are needed.